IWT helps to accelerate reMYND’s Diabetes program with a grant of 1.48 million EUR for 2011-2012
27-06-2011
reMYND NV today announced that it has received a grant of 1.48 million EUR to accelerate its Diabetes program.
Read more
Review in Nature highlights reMYND's discovery platform
15-11-2010
The growing interest in targeting protein misfolding to therapeutically treat both rare and common diseases was featured in Nature Reviews Drug Discovery.
Read more
reMYND receives a grant of 0.9 million EUR from IWT
10-12-2009
reMYND receives a grant of 0.9 million EUR from the Institute for the Promotion of Innovation by Science and Technology in Flanders (IWT).
Read more
reMYND awarded by the Michael J. Fox Foundation
21-07-2009
reMYND is one of the nine biotech and pharmaceutical companies that have been awarded by the Michael J. Fox Foundation
Read more
reMYND receives a grant of almost 1 million EUR from IWT
10-12-2008
reMYND receives a grant of almost 1 million EUR from the Institute for the Promotion of Innovation by Science and Technology in Flanders (IWT).
Read more
reMYND's Lead Alzheimer drug demonstrates neuroprotection
15-11-2008
reMYND's Lead Alzheimer drug demonstrates neuroprotection in 2 transgenic animal models of TAU and Amyloid bèta pathology.
Read more
Lead product for treating Parkinson's Disease demonstrates efficacy
15-03-2008
Lead product for treating Parkinson's Disease demonstrates efficacy in 3 different animal models of Parkinson's Disease.
Read more
reMYND's Parkinson's disease drug discovery program reaches breakthrough
26-03-2007
reMYND nv has reached a breakthrough in its drug discovery program aimed at identifying disease-modifying drugs for the treatment of Parkinson's disease.
Read more